Beacon Hospice Care 4774 Riverside Drive, Suite H, Chino, CA, 91710 | |
(909) 608-7555 |
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
Name | Beacon Hospice Care |
---|---|
Location | 4774 Riverside Drive, Suite H, Chino, California |
Hospice ID | 751732 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | The Joint Commission (TJC) |
SSA county code | 460 |
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
NPI Number | 1245674217 |
Organization Name | Beacon Hospice Care |
Address | 4774 Riverside Dr Chino, California, 91710 |
Phone Number | (909)608-7555 |
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
Home Health Aides | 1 |
Homemakers | 1 |
Licensed Practical or Vocational Nurses | 1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 2 |
Total Employees | 7 |
---|
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
Counselors | 1 |
Total Volunteers | 1 |
---|
News Archive
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
Devices known as brain-machine interfaces could someday be used routinely to help paralyzed patients and amputees control prosthetic limbs with just their thoughts. Now, University of Florida researchers have taken the concept a step further, devising a way for computerized devices not only to translate brain signals into movement but also to evolve with the brain as it learns.
Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.
When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
› Verified 6 days ago
Delta Hospice Of Ca, Inc Location: 14726 Ramona Avenue Suite 200, Chino, California, 91710 Phone: (909) 608-7555 |
Brio Hospice Location: 14712 Pipeline Avenue Ste C, Chino, California, 91709 Phone: (909) 608-7555 |
Angels Hospice Corporation Location: 15220 Central Avenue Unit B, Chino, California, 91710 Phone: (909) 608-7555 |
A-one Hospice Providers, Inc Location: 13788 Roswell Avenue, Chino, California, 91710 Phone: (909) 608-7555 |